רווח נקי למניה (EPS TTM): Quoin Pharma (QNRX)

Is it worth investing in a company developing scientific alliances with funds dedicated to combating rare dermatoses? The change in per-share profit over the last 12 months provides the answer, where the parameter value equals -9.13. The prospects for Quoin Pharmaceuticals (QNRX) depend on the QRX003 trials and orphan drug status, while streamlined supply chains for active components eliminate logistical disruptions.
פילוחי נתונים אנליטיים מרוכזים עבור Quoin Pharmaceuticals (QNRX)

Professional capital evaluates Quoin Pharmaceuticals (QNRX) through the lens of profit generation efficiency per share. The trailing 12-month net income per share aggregates the final financial result for the year, stripping out the influence of the total share count. Analyzing this metric allows for a comparison of real income against inflationary cost pressures. Given the orphan drug status of the products, patent monopolies should maintain the stability of this indicator. Growth in this figure confirms the resilience of the business model and the reliability of the asset.